ethyl (E)-1-{5-[(2-(4-((benzylmethylamino)methyl)benzylidene)-3-oxo-2,3-dihydro-1H-inden-5-yl)oxy]pentyl}-4-phenylpiperidine-4-carboxylate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: ethyl (E)-1-{5-[(2-(4-((benzylmethylamino)methyl)benzylidene)-3-oxo-2,3-dihydro-1H-inden-5-yl)oxy]pentyl}-4-phenylpiperidine-4-carboxylate
• 英文别名: ethyl 1-[5-[[(2E)-2-[[4-[[benzyl(methyl)amino]methyl]phenyl]methylidene]-3-oxo-1H-inden-5-yl]oxy]pentyl]-4-phenylpiperidine-4-carboxylate
• 化学式: C₄₄H₅₀N₂O₄
• 分子量: 670.892
• InChiKey: ALDRVRZUYXXEDQ-DMFHDPHMSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8.4
• 重原子数：
  50
• 可旋转键数：
  16
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  59.1
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  去甲哌替啶 、 2-{4-[(benzylmethylamino)methyl]benzylidene}-6-(5-iodopentyloxy)-2,3-dihydro-1H-indan-1-one 在 三乙胺 作用下， 以 甲苯 为溶剂， 以49%的产率得到ethyl (E)-1-{5-[(2-(4-((benzylmethylamino)methyl)benzylidene)-3-oxo-2,3-dihydro-1H-inden-5-yl)oxy]pentyl}-4-phenylpiperidine-4-carboxylate
  参考文献：
  名称：

  From AChE to BACE1 inhibitors: The role of the amine on the indanone scaffold

  摘要：

  In recent years, a progressive increase in age-related disorders could be observed in most western countries, among which Alzheimer's disease (AD) is one of the most challenging. BACE1 could be seen as an attractive target to develop disease-modifying compounds, and in this context, a new series of hybrid molecules was designed and synthesized, based on a previously identified multitarget lead compound. In particular, the amino side chain was appropriately modified to fit BACE1 as additional target. In vitro testing results pointed out compound 8 (IC50 = 2.49 +/- 0.08 mu M), bearing the bulky bis(4-fluorophenyl)methyl)piperazine substituent, as the most potent BACE1 inhibitor of the series. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2015.05.002

文献信息

• From AChE to BACE1 inhibitors: The role of the amine on the indanone scaffold
  作者：Angela Rampa、Francesca Mancini、Angela De Simone、Federico Falchi、Federica Belluti、Rita Maria Concetta Di Martino、Silvia Gobbi、Vincenza Andrisano、Andrea Tarozzi、Manuela Bartolini、Andrea Cavalli、Alessandra Bisi

  DOI：10.1016/j.bmcl.2015.05.002

  日期：2015.7

  In recent years, a progressive increase in age-related disorders could be observed in most western countries, among which Alzheimer's disease (AD) is one of the most challenging. BACE1 could be seen as an attractive target to develop disease-modifying compounds, and in this context, a new series of hybrid molecules was designed and synthesized, based on a previously identified multitarget lead compound. In particular, the amino side chain was appropriately modified to fit BACE1 as additional target. In vitro testing results pointed out compound 8 (IC50 = 2.49 +/- 0.08 mu M), bearing the bulky bis(4-fluorophenyl)methyl)piperazine substituent, as the most potent BACE1 inhibitor of the series. (C) 2015 Elsevier Ltd. All rights reserved.